$1 Dara­prim? Im­prim­is­Rx fa­cil­i­ty in New Jer­sey hit with FDA warn­ing let­ter

Drug com­pounder Im­prim­is­Rx — which made pub­lic­i­ty in 2015 by of­fer­ing a $1 ver­sion of Dara­prim, the drug at the heart of Mar­tin Shkre­li’s price goug­ing es­capades — has been hand­ed an­oth­er warn­ing let­ter from the FDA over one of its pro­duc­tion sites.

The lat­est let­ter, which was is­sued in late May, says FDA in­ves­ti­gat­ed the Im­prim­is­RX fa­cil­i­ty in Ledge­wood, NJ, with in­spec­tors not­ing de­fi­cien­cies in the site’s prac­tices for the pro­duc­tion of drugs meant to be ster­ile that could put pa­tients at risk. The FDA al­so is­sued a Form 483 and Im­prim­is­Rx re­called some prod­ucts last No­vem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER